Arcus Biosciences Profit Margin 2017-2022 | RCUS
Current and historical gross margin, operating margin and net profit margin for Arcus Biosciences (RCUS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Arcus Biosciences net profit margin as of December 31, 2022 is -237.26%.
|Arcus Biosciences Annual Profit Margins
|Arcus Biosciences Quarterly Profit Margins
||Medical - Biomedical and Genetics
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.